Senores Pharma Q2 & H1FY27 Investor Presentation Highlights Revenue and EBITDA Growth
Senores Pharmaceuticals reported strong Q2 & H1FY27 results with revenue up 25% and 30% respectively. EBITDA surged 38.4% in Q2 and 58.2% in H1. The company expects a better H2FY27 driven by new launches like Zoraya and Amerisyn. They have 34 approved ANDAs and are expanding their CDMO/CMO business.
The investor presentation provides a comprehensive update on financial performance, product pipeline, strategic initiatives, and future outlook, which is material information for investors and analysts.
The announcement details significant year-on-year growth in revenue and EBITDA, along with positive future outlook and strategic expansion initiatives, indicating a favorable financial performance and growth prospects.
Senores Pharmaceuticals Limited has released its Investor Presentation for Q2 & H1FY27, detailing significant financial and operational highlights.
The company reported a 25% revenue growth in Q2 FY27 and 30% for H1 FY27. EBITDA saw a substantial increase of 38.4% in Q2 FY27 and 58.2% for H1 FY27. EBITDA margins also expanded by approximately 290 basis points in Q2 FY27 and 530 basis points in H1 FY27. Cash from operations stood at ₹38 Crore for H1 FY27.
The outlook for H2 FY27 is robust, driven by new product launches including Zoraya and Amerisyn, which are expected to contribute to revenues. R&D intensity remains high at 11% of revenue in H1 FY27. The company's US subsidiary, Amerisyn LLC, is playing a key role in this expansion.
In terms of product portfolio, Senores Pharmaceuticals has 34 approved ANDAs with 153 ANDA products to be launched. They commercialized 3 new strengths in Q2 FY27 and received approval for 1 ANDA and 3 sANDA’s. The CDMO/CMO business is focused on specialty, government supplies, and controlled substances, with a significant opportunity in emerging markets.
Consolidated financial highlights show revenue from operations at ₹192.3 Crore for Q2 FY27 and ₹372.5 Crore for H1 FY27. Profit After Tax (PAT) grew by 24.7% in Q2 FY27 to ₹36.6 Crore and by 32.6% in H1 FY27 to ₹67.0 Crore. The company also provided an update on the utilization of IPO funds, with ₹418.83 Crore utilized out of ₹500.00 Crore as of September 30, 2026. The remaining ₹81.17 Crore is parked in fixed deposits and bank accounts.
Growth strategies include launching products with NDA approval potential in the US, expanding into B2C and Government Sales, enhancing market presence in North America, strategic alliances for CMO/CDMO, inorganic growth, and backward integration. The company possesses USFDA approved manufacturing facilities in the US and India, WHO-GMP compliant facilities, and strong R&D capabilities.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.